TAT (48-57) is a cell-permeable peptide derived from the HIV-1 transactivator of transcription (Tat) protein, encompassing amino acid residues 48 to 57 from the basic domain of HIV Tat.
Tat-NR2BAA is an inactive control peptide of Tat-NR2B9c. It shares a similar sequence with Tat-NR2B9c, but possesses a double-point mutation in the COOH terminal tSXV motif. This mutation renders Tat-NR2BAA unable to bind PSD-95. Tat-NR2B9c, on the other hand, is a membrane-permeable peptide that interferes with PSD-95 NMDAR binding. This interference leads to the decoupling of NR2B- and or NR2A-type NMDARs from PSD-95[1][2].
Biotin-TAT (47-57) is a biotin-tagged transactivator of transcription, commonly employed as a protein transduction domain (PTD) in various primary cells. Its transduction capacity is contingent on ATP and temperature, suggesting the participation of endocytosis.
(Cys47)-HIV-1 tat Protein (47-57) possesses membrane translocation functionality and can serve as a surface derivatization agent for magnetic pharmaceuticals, thereby enhancing their uptake into specific target cells.
TAT-Gap19(I130A) is a control peptide for TAT-Gap19, a Cx43 hemichannel blocker. TAT-Gap19(I130A) consists of TAT-GAP19 with a I130A amino acid residue change at a key residue for GAP19 activity. In C6 glioma cells expression Cx43, TAT-GAP19(1130A) does not inhibit [Ca2+]i-triggered ATP release at 200 μM. TAT-Gap19(I130A) is cell permeable.